Switzerland is narrowing the gap with other European countries when it comes to the cost of medicines. But generics are still double the price and harder to find in the Alpine nation.
This content was published on
2 minutes
Keystone-SDA/jdp
The 11th annual analysisExternal link by the industry association Interpharma and the umbrella group of health insurers santésuisse found that patent-protected drugs were on average 4.5% cheaper in the nine reference countries than in Switzerland. This is an improvement from the price difference of 7% last year. Original products that have expired are 10% less abroad.
The price gap remains the largest for generics. In Switzerland, generics are 42% more expensive – a slight decrease from the previous year (48%). They are also less common. According to data from the Organisation for Economic Cooperation and Development (OECD), the share of generics in Switzerland is 27%, compared to 83% in Germany.
The price reductions have helped save CHF1 billion ($1.09 billion) since 2012 according to Interpharma. Medicines account for around 12% of total healthcare costs in Switzerland.
“Insurance premium payers are still spending around CHF200 million more than in the comparison countries, including for patented medicines. The savings could be even greater for generics,” said Verena Nold, director of santésuisse.
The analysis attributes the lower prices to regular price reviews by Swiss public health authorities as well as evolution in exchange rates.
Interpharma also points out that it is taking longer for new, innovative products to be included on the list for health insurance reimbursement. Last year, only 24% of the products that applied for reimbursement were added to the drug specialties listExternal link within 60 days. The number of applications that were not included for reimbursement reached a new high in 2019 with 136 products.
The nine European countries included in the comparison are Germany, Austria, Belgium, Denmark, Finland, France, Great Britain, the Netherlands and Sweden.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Man charged with flying drone at women’s Euro 2025
This content was published on
A man flew a drone around the venue on Wednesday evening during the first match of the Women's EURO 2025 in St. Gallen. The 30-year-old violated the absolute ban on flying during match days. He was reported to the police.
More than 250 Swiss companies sign CO2 reduction initiative
This content was published on
A total of 257 companies from Switzerland have signed up to the Science Based Targets Initiative (SBTi). In doing so, they are committing to CO2 reduction targets that are compatible with the Paris Climate Agreement.
Swiss accident prevention group sees federal targets at risk
This content was published on
The Swiss government's target for accident figures is at risk, reckons Mario Cavegn, member of the executive board of the Swiss Council for Accident Prevention.
Feminicide: Swiss justice minister calls for electronic monitoring
This content was published on
Swiss Justice Minister Beat Jans has called for electronic monitoring and an ankle bracelet warning system for perpetrators of violence against women.
This content was published on
American artist Chaka Khan ‘and friends’ opened the 59th Montreux Jazz Festival on Friday. For over three hours, their show, dedicated to their friend and mentor Quincy Jones, thrilled the audience,
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Generic drugs remain twice as expensive in Switzerland
This content was published on
Drug prices in Switzerland remain higher than in other major European markets, especially when it comes to generic drugs, which are twice as expensive in Switzerland as elsewhere.
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
This content was published on
Switzerland could save millions of francs by prescribing low-priced biotech drug copies, known as biosimilars, instead of expensive biologicals.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.